Imatinib had no impact on failure-free or overall survival in patients with gastrointestinal stromal tumor, but it did have an effect on relapse-free survival.
Gastrointestinal Stromal Tumor
The risk of bone metastases from GISTs, though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases.
Pathologic and molecular features of gastrointestinal stromal tumors (GIST) were generally not correlated with outcome in a study involving adjuvant imatinib therapy following resection of the primary tumor.
This slide show features a CT image, and pathology images of gastrointestinal stromal tumors (GISTs) arising in the stomach using H&E, CD34, and c-Kit staining.
The results of a retrospective study indicated that patients with metastatic GIST who are able to achieve complete macroscopic surgical resection of their disease may be able to achieve long-term survival.
A recent exploratory study found that GIST cells showed unexpected sensitivity to certain kinds of chemotherapy drugs not typically associated with the diseases’ treatment.
The preoperative diagnosis of combined gastric gastrointestinal stromal tumor (GIST) and gastric cancer is often missed, according to the results of a recent study.
Patients with heavily pretreated metastatic gastrointestinal stromal tumors were able to tolerate combined treatment with the pan-deacetylase inhibitor panobinostat and imatinib, according to the results of a small phase I study.
A phase II trial showed that patients with advanced gastrointestinal stromal tumors had a marginal response to pazopanib when assigned to the treatment after two or more failed therapies.
Results of a small study indicate that patients with gastrointestinal stromal tumors had increased activity of Src, but unlike in other tumors, it may be associated with longer overall survival.